Finally, no current discussion about making a difference can be complete without mention of health care reform policies to promote access to the most effective treatments. Even as more evidence-based treatments become available and as we see growing sophistication in our capacity to construct sequenced treatment, as exemplified in the Bowie et al. study, the common failure to make even one evidence-based treatment available in many communities underscores the challenges. It is not at all clear how proposed changes in health care law and policy will promote the implementation of personalized, sophisticated treatment regimens (7). The resources needed to implement the interventions examined by Bowie et al. seem modest but include computers and software for cognitive training, doctoral-level therapists to conduct both cognitive remediation therapy and functional adaptation skills training, and training and ongoing monitoring for staff to implement and maintain fidelity of the interventions. Such innovation requires a commitment from agency leaders to prioritize these approaches. This type of “retooling” of rehabilitation programs requires considerable perseverance, especially if existing resources need to be redirected. How would outcomes improve, for example, if we combined the personalized approach to pharmacotherapy envisioned by Apud et al. with the sequenced psychosocial regimen presented by Bowie et al. among young persons experiencing the early phases of schizophrenia? How much would it cost to achieve this? How much does it cost not to do this? Costs may at times dominate the national debate on mental health coverage, but this is all the more reason to have evidence that treatments can make a meaningful difference. As we move forward, we have to be concerned that the types of treatments presented by Bowie et al. may be vulnerable under new insurance plans that will likely emphasize core medical services and leave rehabilitation services increasingly vulnerable to mightily challenged state and local budgets (8). Pardes pointed out some years ago (9) that as technologies advance to improve the outcomes for a given medical condition, costs to treat that condition typically rise, at least until a cure is found. To make a difference in the real-world outcomes for persons with schizophrenia, we will need to invest smartly and to argue persuasively for greater parity based on the evidence.